New York, NY -- (SBWIRE) -- 01/03/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Globalstar, Inc (OTCMKTS:GSAT), New Residential Investment Corp (NYSE:NRZ), ERBA Diagnostics Inc (NYSEMKT:ERB), Exelixis, Inc (NASDAQ:EXEL)
Globalstar, Inc (OTCMKTS:GSAT) showed a volume of 1.78 million shares by the end of last trade whereas the average volume of the stock remained 3.82 million shares. The stock opened the session at $1.76 but then moved to $1.72. At that price, the stock showed a negative performance of -1.71%. Globalstar, Inc. (Globalstar) is a provider of mobile voice and data communications services globally via satellite. Globalstar’s satellite communications business, by providing critical mobile communications to the Company's subscribers, serves principally recreation and personal; government; public safety and disaster relief; oil and gas; maritime and fishing; natural resources, mining and forestry; construction; utilities and transportation.
Will GSAT Get Buyers Even After The Recent Rally? Find Out Here
New Residential Investment Corp (NYSE:NRZ) opened the session at $6.68 and closed the session at $6.66. The stock showed a negative performance of -0.30% in previous trading session. New Residential Investment Corp., incorporated on September 26, 2013, is a real estate investment trust. The Company focuses on investing in, and actively managing, investments related to residential real estate. The Company is managed by an affiliate of Fortress Investment Group LLC,
Has NRZ Found The Bottom And Ready To Gain Momentum? Find Out Here
ERBA Diagnostics Inc (NYSEMKT:ERB) opened the session at $2.87 and closed the session at $3.90. The stock showed a positive performance of 42.86% in previous trading session. Traded with volume of 1.75 million shares in the prior session and the average volume of the stock remained 177,993.00 shares. The beta of the stock remained 0.71. ERBA Diagnostics, Inc., through its subsidiaries, is engaged in developing, manufacturing and marketing diagnostic test kits, reagents and instruments for use in hospitals, reference laboratories, clinical laboratories, research laboratories, doctors' offices and other commercial companies. The Company’s products and instrumentation are sold primarily to customers in the United States and Italy. These tests, which are designed to aid in the identification of the causes of illness and disease, assist physicians in selecting appropriate patient treatment.
Why Should Investors Buy ERB After The Recent Gain? Just Go Here and Find Out
Exelixis, Inc (NASDAQ:EXEL) the stock advanced 0.82% and finished the session at $6.18. Traded with volume of 1.74 million shares in the prior session and the average volume of the stock remained 1.35 million shares. The beta of the stock remained 1.97. Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.
Will EXEL Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)